Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics Partners with Bayer on Asthma Gene Expression Research

NEW YORK, June 13 – Galapagos Genomics is collaborating with Bayer Yakuhin of Japan to identify and evaluate the function of proteins associated with asthma, the company announced Wednesday.

Galapagos, of Mechelen, Belgium, will construct recombinant adenoviruses containing asthma-associated human genes supplied by  Bayer Yakuhin, a subsidiary of German pharmaceutical giant Bayer. Bayer Yakuhin will then use the viruses to introduce the genes into human cells, in order to discern how the proteins encoded by these genes work at a cellular level.

The parties did not disclose the financial terms of the collaboration.

Galapagos, a privately held company, has developed a PhenoSelect expression platform technology, in which it has arrayed adenoviruses with human genes. The company will use this proprietary platform in its collaboration.

“This is Galapagos’ first collaboration with a top-tier pharmaceutical company and it is therefore an important milestone for the company,” Galapagos CEO Onno van de Stolpe said in a statement. “This collaboration is an endorsement of our platform as an important tool in the rapid identification and validation of drug targets out of large gene collections.”

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.